ClinicalTrials.gg
CompletedNCT01098734Updated Jun 13, 2011

Non-steroid, Atopic Dermatitis Phase IIb 12-week Trial; Topical WBI-1001 Cream

A Phase 2 interventional study of WBI-1001 in Dermatitis, Atopic, sponsored by Welichem Biotech Inc.. Completed at 5 sites in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-06-13.

Sponsored by Welichem Biotech Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing tapinarof in Dermatitis, Atopic — 1 open to participants now, 2 under way, 1 of them phase 3. tapinarof · Dermatitis, Atopic.

Enrollment
7th of 12
148 · median 168
Started
2009
the only one that year
Phase 2
3 of 12
none open now
Registered
2nd of 12
by date
Lead sponsor
2 of 12
Welichem Biotech Inc.

Among the 12 studies testing tapinarof in Dermatitis, Atopic, this one is the 7th largest by enrollment, is the only one that started in 2009, is one of 3 in phase 2, and was the 2nd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

1 of the 12 studies testing tapinarof in Dermatitis, Atopic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About tapinarof

tapinarof: first FDA approval 2022 (VTAMA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing tapinarof in Dermatitis, Atopic, or all of them as a file.
02

Study summary

Welichem Biotech has developed a small molecule drug candidate, WBI-1001, that selectively targets the pathogenic features of inflammatory skin diseases, including atopic dermatitis (a form of eczema).The purpose of this clinical trial is to further test the safety and efficacy of WBI-1001 as a topically applied cream over an extended period of 12 weeks on patients with mild to moderate atopic dermatitis.

Read the detailed description

A multi-centered, double-blinded Phase IIb study to evaluate the safety and efficacy of the non-steroid, anti-inflammatory WBI-1001 cream in the topical treatment of patients with mild to moderate atopic dermatitis, expressed as lesions up to 20% BSA. For the first 6 weeks patients will be randomized to one of three treatment groups simultaneously in a ratio of 1:1:1.

Group 1: vehicle cream (placebo), BID; Group 2: 0.5% WBI-1001 cream, BID; Group 3:1.0% WBI-1001 cream, BID. Patients randomized to treat all lesion areas.

After the first 6 weeks all patients will be treated, non-placebo controlled, with WBI-1001 cream. The Group 1 patients will enter a double-blinded phase for a further 6 weeks with half of them being treated BID with 0.5% and half with 1.0% WBI-1001 cream. Groups 2 and 3 will continue with their treatments unchanged for the remaining 6 weeks.

During the treatment period, patients will apply the cream (BID) from the kit that they have been provided, and they will visit the study centre at prescribed times for assessment of efficacy, safety and tolerability. After completion of the 12-week treatment period patients will have a 2-week follow-up visit.

Patients who withdraw from the study before Day 42 for reasons other than a treatment related AE will be replaced so that at least 40 patients per group will complete the placebo-controlled phase.

03

Conditions studied

  • Dermatitis, Atopic

Keywords

  • non-steroid
  • anti-inflammatory
  • skin disease
  • topical cream
  • small molecule
  • atopic dermatitis
  • eczema
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of chronic atopic dermatitis (Hanifin's criteria) for greater than 6 months with a minimum of 5% and a maximum of 20% BSA.
  • IGA scores of 2-4 at Day 0.
  • must have a negative serum beta-hCG pregnancy test before randomization, and they and their male partners must take pregnancy precautions for the duration of the study, as also must male patients.
  • Willing to comply with Protocol and attend all visits.
  • Provide written prior to entering study procedures.
  • Patient has no latent or active tuberculosis infection according to medical history or current examination and tests.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation.
  • Spontaneously improving or rapidly deteriorating atopic dermatitis.
  • Presence of atopic dermatitis on only hands and/or feet.
  • Any skin disease other than atopic dermatitis that might interfere with clinical assessment or put patient at risk.
  • Active allergic contact dermatitis or other non-atopic forms of atopic dermatitis.
  • Other concommitant serious illness or medical condition, virus or renal insufficiency, or abnormality that could put patient at risk during the study.
  • History of neurological/psychiatric disorders including psychotic disorders, dementia or any other reason that would interfere with the patient's participation.
  • Systemic immunomodulatory therapies for other conditions within 4 weeks prior to the baseline visit.
  • Any phototherapy, photochemotherapy or systemic atopic dermatitis therapy within 2 weeks of the baseline visit.
  • Prolonged exposure to natural or artificial sources of UV within 4 weeks prior to baseline visit or intention to have such exposure during the study.
  • Topical atopic dermatitis therapies (including and calcineurins) in the areas to be treated within 2 weeks prior to baseline.
  • Alcohol abuse in the last 2 years.
  • Allergic history to any of the non-medical ingredients of the study cream.
  • Treatment with an drug within one month of Day 0 or current participation in another clinical trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
148 participants (actual)

Study arms

  • Placebo comparator
    Group 1

    0%; vehicle cream

    Drug: WBI-1001

  • Active comparator
    Group 2

    0.5% WBI-1001 cream

    Drug: WBI-1001

  • Active comparator
    Group 3

    1.0% WBI-1001 cream

    Drug: WBI-1001

Interventions

  • A 12-week study to assess the efficacy, safety and tolerability of topically applied WBI-1001 creams. First 6 weeks will be double-blinded, placebo-controlled and the following 6 weeks will be double-blinded, non-placebo- controlled. After 6 weeks patients in Groups 2 and 3 will continue double-blinded treatment for a further 6 weeks, but patients in Group 1 will enter a 6-week double-blinded phase with one of the two active creams (half treated with 0.5% and half with 1.0% WBI-1001 cream). All patients treated twice daily (BID).

06

What researchers measure

Primary outcomes

  1. Investigator's Global Assessment (IGA) score

    To evaluate the efficacy of the 0.5% and 1.0% WBI-1001 creams in comparison with the vehicle placebo.

    Time frame: The change from baseline to 6 weeks.

Secondary outcomes

  1. Eczema Area and Severity Index (EASI) score

    Comparison over time with the placebo.

    Time frame: The change from baseline to 6 weeks.

  2. Scoring Atopic Dermatitis (SCORAD) Index.

    Comparison over time with the placebo.

    Time frame: Change from baseline to 6 weeks.

  3. Clinical laboratory tests (haematology, urine) and vital signs.

    Time frame: From baseline through 12 weeks+2 weeks follow-up

  4. Adverse events

    Time frame: From baseline through 12 weeks+2 weeks follow-up

  5. BSA and pruritus.

    Comparison over time with placebo.

    Time frame: From baseline through 6 weeks.

  6. Longterm change in IGA score of WBI-1001 cream groups.

    Long term comparison, non-placebo, of the 0.5% and 1.0% cream treated groups of patients

    Time frame: Change from baseline through 12 weeks

  7. Statistically significant improvement in the rate of "Treatment Success" with 0.5% and 1.0% WBI-1001 creams compared with placebo.

    "Treatment Success" is defined as a patient who (1) achieves "clear" (IGA=0) or "almost clear" (IGA=1) on a five-point IGA scale or (2) has a minimum of 2-point improvement in IGA score over the baseline.

    Time frame: First 6 weeks

07

Study locations

5 sites
  • Guilford Dermatology Associates
    Surrey, British Columbia V3R 6A7, Canada
  • Department of Dermatology and Skin Sciences, UBC
    Vancouver, British Columbia V5Z 4E8, Canada
  • Windsor Clinical Research Inc.
    Windsor, Ontario N8W 6A7, Canada
  • Innovaderm Research Inc.
    Montreal, Quebec H2K 4L5, Canada
  • Centre de Recherche Dermatologique du Quebec
    Quebec City, Quebec G1V 4X7, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Oct 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2010
First posted
Apr 5, 2010
Start
Nov 2009
Primary completionActual
Oct 2010
CompletionActual
Nov 2010
Last update
Jun 13, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01098734
Lead sponsor
Welichem Biotech Inc.
First posted
Apr 5, 2010
Start date
Nov 2009
Primary completion
Oct 2010
Completion
Nov 2010
Last update
Jun 13, 2011

Study contacts

Liren Tang, Ph.D
study director · Sponsor GmbH

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tapinarof

Start the discussion